USD 1.28
(4.51%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 | 11.7 Million USD | 33.61% |
2023 | 8.76 Million USD | 5.11% |
2022 | 8.33 Million USD | 18.55% |
2021 | 7.03 Million USD | 148.68% |
2020 | 2.82 Million USD | -57.98% |
2019 | 6.72 Million USD | 46.19% |
2018 | 4.6 Million USD | 2561.01% |
2017 | 172.99 Thousand USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 FY | 9.25 Million USD | 5.65% |
2024 Q1 | 2.75 Million USD | 2.56% |
2024 Q2 | 2.19 Million USD | -20.59% |
2024 Q3 | 2.89 Million USD | 32.25% |
2024 Q4 | 3.62 Million USD | 25.2% |
2023 Q4 | 2.68 Million USD | 8.47% |
2023 FY | 8.76 Million USD | 5.11% |
2023 Q3 | 2.47 Million USD | 4.42% |
2023 Q2 | 2.37 Million USD | 94.93% |
2023 Q1 | 1.21 Million USD | -41.65% |
2022 Q2 | 3.46 Million USD | 140.85% |
2022 Q4 | 2.08 Million USD | 55.5% |
2022 Q3 | 1.34 Million USD | -61.26% |
2022 Q1 | 1.43 Million USD | -37.73% |
2022 FY | 8.33 Million USD | 18.55% |
2021 Q4 | 2.31 Million USD | -26.4% |
2021 Q1 | 658.59 Thousand USD | 31.21% |
2021 Q2 | 917.32 Thousand USD | 39.29% |
2021 FY | 7.03 Million USD | 148.68% |
2021 Q3 | 3.14 Million USD | 242.36% |
2020 Q1 | 615.36 Thousand USD | -79.66% |
2020 FY | 2.82 Million USD | -57.98% |
2020 Q3 | 179.49 Thousand USD | -89.47% |
2020 Q4 | 501.93 Thousand USD | 179.64% |
2020 Q2 | 1.7 Million USD | 176.9% |
2019 Q3 | 1.44 Million USD | 0.0% |
2019 FY | 6.72 Million USD | 46.19% |
2019 Q4 | 3.02 Million USD | 109.46% |
2019 Q1 | 1.5 Million USD | -16.03% |
2018 Q3 | 756.28 Thousand USD | 0.0% |
2018 Q4 | 1.79 Million USD | 137.18% |
2018 FY | 4.6 Million USD | 2561.01% |
2017 FY | 172.99 Thousand USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
OpGen, Inc. | 30.65 Million USD | 61.808% |
Standard BioTools Inc. | 113.48 Million USD | 89.683% |
Aspira Women's Health Inc. | 24.11 Million USD | 51.444% |
bioAffinity Technologies, Inc. | 8.76 Million USD | -33.588% |
Castle Biosciences, Inc. | 242.78 Million USD | 95.177% |
Exact Sciences Corporation | 2.06 Billion USD | 99.432% |
IDEXX Laboratories, Inc. | 1.09 Billion USD | 98.929% |
iSpecimen Inc. | 16.27 Million USD | 28.067% |
Inotiv, Inc. | 246.9 Million USD | 95.258% |
Psychemedics Corporation | 11.33 Million USD | -3.307% |
RadNet, Inc. | 268.87 Million USD | 95.645% |
Prenetics Global Limited | 60.73 Million USD | 80.722% |
Neuronetics, Inc. | 82.25 Million USD | 85.766% |
Star Equity Holdings, Inc. | 16.27 Million USD | 28.043% |
Exagen Inc. | 52.29 Million USD | 77.609% |
Bionano Genomics, Inc. | 148.99 Million USD | 92.141% |
CareDx, Inc | 277.76 Million USD | 95.785% |
Check-Cap Ltd. | 19.28 Million USD | 39.292% |
Twist Bioscience Corporation | 354.18 Million USD | 96.694% |
Guardant Health, Inc. | 901.62 Million USD | 98.701% |
Biodesix, Inc. | 77.41 Million USD | 84.876% |
BioNexus Gene Lab Corp. | 3.92 Million USD | -198.459% |
Precipio, Inc. | 13.63 Million USD | 14.146% |
Natera, Inc. | 938.98 Million USD | 98.753% |
Fulgent Genetics, Inc. | 171.9 Million USD | 93.189% |
Sera Prognostics, Inc. | 39.91 Million USD | 70.667% |
23andMe Holding Co. | 420.73 Million USD | 97.217% |
OPKO Health, Inc. | 574.68 Million USD | 97.963% |
Personalis, Inc. | 128.14 Million USD | 90.863% |
Aclaris Therapeutics, Inc. | 110.52 Million USD | 89.406% |
Applied DNA Sciences, Inc. | 16.48 Million USD | 28.98% |
T2 Biosystems, Inc. | 41.49 Million USD | 71.782% |
Neogen Corporation | 405.23 Million USD | 97.111% |
Myriad Genetics, Inc. | 600.1 Million USD | 98.049% |
ICON Public Limited Company | 755.64 Million USD | 98.45% |
NeoGenomics, Inc. | 341.25 Million USD | 96.569% |
Star Equity Holdings, Inc. | 16.27 Million USD | 28.043% |
MDxHealth SA | 71.25 Million USD | 83.568% |
Prenetics Global Limited | 60.73 Million USD | 80.722% |
Illumina, Inc. | 3.81 Billion USD | 99.693% |
DarioHealth Corp. | 62.17 Million USD | 81.167% |
ENDRA Life Sciences Inc. | 10.52 Million USD | -11.293% |
Medpace Holdings, Inc. | 187.68 Million USD | 93.761% |
Mainz Biomed B.V. | 27.15 Million USD | 56.881% |
Trinity Biotech plc | 46.49 Million USD | 74.817% |
Sotera Health Company | 300.46 Million USD | 96.103% |
bioAffinity Technologies, Inc. | 8.76 Million USD | -33.588% |